Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer
This pilot clinical trial studies low-dose acetylsalicylic acid in treating patients with stage I-III non-small cell lung cancer. Studying samples of urine and blood from patients with cancer in the laboratory may help doctors learn more about changes in biomarkers that occur during treatment with acetylsalicylic acid
Checked against the public recordLast updated Jan 14, 2020 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Basic Science
- Study type
- Interventional
- Phase
- Early Phase 1
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Interventions being studied
- Drug: acetylsalicylic acid; Other: laboratory biomarker analysis
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Have confirmed (stage IIIb-IV) or recurrent non-small cell lung cancer, adenocarcinoma histology * Understand and voluntarily sign an informed consent document prior to any study related assessments or procedures are conducted * Anticipated that they will complete all study procedures * Ability to swallow pills * No aspirin in the last 7 days Exclusion Criteria: * Know allergy to aspirin or other nonsteroidal anti-inflammatory drugs * History of allergic reaction to aspirin or other non-steroidal anti-inflammatory drugs, including ibuprofen * Any other concomitant serious illness or organ system dysfunction which in the opinion of the investigator would either compromise patient safety
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Vanderbilt-Ingram Cancer CenterNashville, Tennessee
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 14, 2020. Always confirm current availability with the study team.